# RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial

Study · id `cardio:ct-nct02303795` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02303795](<https://clinicaltrials.gov/study/NCT02303795>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02303795

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1005 participants.

## Technical summary

Registry record NCT02303795. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2020-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 1005 participants (enrolled count; ClinicalTrials.gov record NCT02303795, source copy `cardio:ctgov-nct02303795-2022-04-12`, retrieved 2026-10-26)
- Started: 2015-08 (actual) (ClinicalTrials.gov record NCT02303795, source copy `cardio:ctgov-nct02303795-2022-04-12`, retrieved 2026-10-26)
- Primary completion: 2020-08 (actual) (ClinicalTrials.gov record NCT02303795, source copy `cardio:ctgov-nct02303795-2022-04-12`, retrieved 2026-10-26)
- Completion: 2020-08 (actual) (ClinicalTrials.gov record NCT02303795, source copy `cardio:ctgov-nct02303795-2022-04-12`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT02303795, source copy `cardio:ctgov-nct02303795-2022-04-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02303795-2022-04-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
- Condition: Valvular Heart Disease
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Warfarin
- Lead sponsor: Hospital do Coracao
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Hospital do Coracao (`cardio:org-hospital-do-coracao`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve (`cardio:pubmed-33196155`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a33cc0708b2581e8280eaeea571f068e8300cfb720c55525834631f0568d8595
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
